Research Progress of Mesenchymal Stem Cell Therapy for Severe COVID-19
| Autor: | Wen-Hua Jiang, Liming Hao, Qi-Qi Cai, Fei Yin |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Pulmonary Fibrosis
Anti-Inflammatory Agents Lung injury Biology medicine.disease_cause Mesenchymal Stem Cell Transplantation Antioxidants Immunomodulation Fibrosis Pulmonary fibrosis medicine Humans Coronavirus SARS-CoV-2 Mesenchymal stem cell COVID-19 Mesenchymal Stem Cells Cell Biology Hematology Lung Injury medicine.disease Pneumonia Oxidative Stress Immunology Cytokine storm Cytokine Release Syndrome Developmental Biology Homing (hematopoietic) |
| Zdroj: | Stem cells and development. 30(9) |
| ISSN: | 1557-8534 |
| Popis: | Corona virus disease 2019 (COVID-19) refers to a type of pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Sixty million confirmed cases have been reported worldwide until November 29, 2020. Unfortunately, the novel coronavirus is extremely contagious and the mortality rate of severe and critically ill patients is high. Thus, there is no definite and effective treatment in clinical practice except for antiviral therapy and supportive therapy. Mesenchymal stem cells (MSCs) are not only characterized by low immunogenicity and homing but also have anti-inflammatory and immunomodulation characteristics. Furthermore, they can inhibit the occurrence and development of a cytokine storm, inhibit lung injury, and exert antipulmonary fibrosis and antioxidative stress, therefore MSC therapy is expected to become one of the effective therapies to treat severe COVID-19. This article will review the possible mechanisms of MSCs in the treatment of severe COVID-19. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|